Equities researchers at StockNews.com started coverage on shares of Alimera Sciences (NASDAQ:ALIM – Get Free Report) in a research note issued to investors on Saturday. The firm set a “hold” rating on the biopharmaceutical company’s stock.
A number of other equities research analysts have also weighed in on the stock. Alliance Global Partners reaffirmed a “neutral” rating on shares of Alimera Sciences in a research note on Tuesday, June 25th. Maxim Group reiterated a “hold” rating on shares of Alimera Sciences in a report on Tuesday, June 25th. Finally, HC Wainwright cut Alimera Sciences from a “buy” rating to a “neutral” rating and set a $6.00 target price for the company. in a research note on Tuesday, June 25th.
View Our Latest Research Report on Alimera Sciences
Alimera Sciences Stock Down 0.2 %
Alimera Sciences (NASDAQ:ALIM – Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). Alimera Sciences had a negative net margin of 14.74% and a negative return on equity of 33.70%. The firm had revenue of $27.00 million during the quarter, compared to analysts’ expectations of $25.76 million. Equities research analysts forecast that Alimera Sciences will post -0.13 EPS for the current year.
Hedge Funds Weigh In On Alimera Sciences
Large investors have recently made changes to their positions in the business. Fifth Lane Capital LP purchased a new stake in shares of Alimera Sciences in the 1st quarter worth approximately $83,000. Rhumbline Advisers purchased a new stake in shares of Alimera Sciences in the second quarter worth $113,000. Hillsdale Investment Management Inc. bought a new position in shares of Alimera Sciences during the first quarter valued at $169,000. Bank of New York Mellon Corp purchased a new position in shares of Alimera Sciences in the 2nd quarter worth about $344,000. Finally, Gabelli Funds LLC purchased a new position in shares of Alimera Sciences in the 2nd quarter worth about $600,000. 99.83% of the stock is currently owned by hedge funds and other institutional investors.
About Alimera Sciences
Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).
Read More
- Five stocks we like better than Alimera Sciences
- Airline Stocks – Top Airline Stocks to Buy Now
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- Election Stocks: How Elections Affect the Stock Market
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- Learn Technical Analysis Skills to Master the Stock Market
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.